21.5 C
New York
Wednesday, June 7, 2023

Insights Into CymaBay Therapeutics Inc. (CBAY) Exposure By Institutions

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for CymaBay Therapeutics Inc. (CBAY) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.08, or -0.94%, to $8.42. The CymaBay Therapeutics Inc. has recorded 5,933 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

CymaBay Therapeutics Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $8.50 and fluctuated between $8.64 as its day high and $8.39 as its day low. The current market capitalization of CymaBay Therapeutics Inc. is $821.78M. A total of 0.96 million shares were traded on the day, compared to an average of 1.65M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, CBAY has seen 3 BUY and 3 SELL insider trades, representing the acquisition of 120,100 and the disposition of 120,100 shares. Over the last 12 months, there were 4 BUYs and 3 SELLs from insiders. Insiders purchased 171,401 shares during that period but sold 120,100.

In the most recent transaction, McWherter Charles sold 21,749 shares of CBAY for 9.08 per share on May 18. After the transaction, the President of R&D now owns 15,000 company shares. In a previous transaction on May 15, Quinlan Paul T sold 5,000 shares at 10.37 per share. CBAY shares that General Counsel owns now total 0.

Among the insiders who sold shares, KIM DENNIS D disposed of 112,219 shares on Apr 17 at a per-share price of $9.54. This resulted in the Chief Medical Officer holding 20,000 shares of CBAY after the transaction. In another insider transaction, KIM DENNIS D sold 7,781 shares at $8.98 per share on Apr 13. Company shares held by the Chief Medical Officer now total 20,000.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for CBAY in the last 3 months, the mean price target is $14.20 with high estimates of $19.00 and low estimates of $8.00. In terms of 52-week highs and lows, CBAY has a high of $11.22 and a low of $1.81.

As of this writing, CBAY has an earnings estimate of -$0.19 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of $0.04 per share and a lower estimate of -$0.31.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. CBAY’s latest balance sheet shows that the firm has $186.53M in Cash & Short Term Investments as of fiscal 2021. There were $51.58M in debt and $18.37M in liabilities at the time. Its Book Value Per Share was $1.06, while its Total Shareholder’s Equity was $132.94M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CBAY is Buy with a score of 5.00.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles